Biologically active substance, process for preparing the substance and immunoactive composition

Claim 2

A process for preparing a biologically active substance which is a glycoprotein having a molecular weight of 3,000 to 5,000 as determined by a gel filtration method and having activity to inhibit toxoplasma multplication not only in homologous cells but also in heterologous cells, and further having the following physical and chemical properties: (a) solubility: freely soluble in water and practically insoluble in methanol, ethanol, ehter, benzene, chloroform and acetone; (b) constituent amino acid of protein portion: aspartic acid, threonine, serine, glutamic acid, glycine, alanine, cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, lysine, tryptophan, histidine, arginine and proline; (c) aspartic acid, glutamic acid and lysine contents in total amino acids: 45 to 65% by weight; (d) pH; 7.0 to 7.2 (1 W/V % aqueous solution); (e) thermal stability: when 1 W/V % aqueous solution of the substance is heated at 60°±0.1° C. for 30 minutes, the solution still retains the immunoactivity to inhibit toxoplasma multiplication in homologous cells and heterologous cells; (f) IR adsorption: characteristic adsorption at the following wave number (cm -1 ): 3600-2900 (strong), 1700-1500 (strong), 1440-1380 (medium), 1160-1080 (medium), and 550 (medium); (g) UV absorption: maximum absorption is found at 274-276 nm for 0.1 W/V % aqueous solution; (h) color reaction: positive Lowry-Folin process, Ninhydrin reaction, Phenol-sulfuric acid reaction and Elso-Morgan's reaction; (i) color and appearance: white and amorphous; the process comprising the steps of contacting at least one starting material selected from the group consisting of (A) blood plasma or serum obtained from a mammal hyperimmunized with a protozoan selected from the group consisting of Toxoplasma, Plasmodium and Babesia, (B) a culture supernatant of spleen cells from a mammal hyperimmunized with said protozoan, and (C) a culture supernatant of spleen cells from a normal mammal incubated in the presence of at least one of the supernatant (B) and a protozoan lysate antigen selected from the group consisting of Toxoplasma lysate antigen (TLA), Plasmodium lysate antigen (PLA) and Babesia lysate antigen (BLA); with a proteolytic enzyme at a concentration and for a time sufficient to liberate said glycoprotein from said starting material, heating the resulting lysate to inactivate the enzyme, separating and isolating said glycoprotein from the lysate.

Claim 3

A process as defined in claim 1 wherein the reaction of the enzyme with the starting material is followed by hydrolysis of the resulting mixture with use of alkali at a pH of at least 12 at 90° to 100° C. for about 60 minutes.

Claim 4

A process as defined in claim 2 wherein the protozoan is selected from the group consisting of Toxoplasma gondii, Plasmodium berghei NK strain, Babesia gibsoni, Babesia rhodhaini, Babesia ovata and Babesia sergenti.

Claim 5

A process as defined in claim 2 wherein the proteolytic enzyme is selected from the group consisting of pronase, papain, chymotrypsin, trypsin, aminopeptidase and carboxypeptidase.

Claim 6

A process as defined in claim 1 wherein the protozoan is Toxoplasma.

Claim 7

A process as defined in claim 3 wherein the protozoan is Toxoplasma gondii.

Claim 8

A process as defined in claim 1 wherein the starting material is (A) blood plasma or serum obtained from a mammal hyperimminized with a protozoan selected from the group consisting of Toxoplasma, Plasmodium and Babesia.

Claim 9

A process as defined in claim 1 wherein the starting material is (B) a culture supernatant of spleen cells from a mammal hyperimmunized with a protozoan selected from the group consisting of Toxoplasma, Plasmodium and Babesia.

Claim 10

A process as defined in claim 1 wherein the starting material is (C) a culture supernatant of spleen cells from a normal mammal incubated in the presence of at least one of the supernatant (B) and a protozoan lysate antigen wherein said lysate antigen is selected from the group consisting of Toxoplasma, Plasmodium and Babesia.

Claim 11

A process for preparing a biologically active substance which is a glycoprotein having a molecular weight of 3,000 to 5,000 as determined by a gel filtration method and having activity to inhibit toxoplasma multiplication not only in homologous cells but also in heterologous cells, and further having the following physical and chemical properties: (a) solubility: freely soluble in water and practically insoluble in methanol, ethanol, ether benzene, chloroform and acetone; (b) constituent amino acid of protein portion: apartic acid, threonine, serine, glutamic acid, glycine, alanine, cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, lysine, tryptophan, histidine, arginine and proline; (c) aspartic acid, glutamic acid and lysine contents in total amino acids: 45 to 65% by weight; (d) PH: 7.0 to 7.2 (1 W/V % aqueous solution); (e) thermal stability: when 1 W/V % aqueous solution of the substance is heated at 60°±0.1° C. for 30 minutes, the solution still retains the immunoactivity to inhibit toxoplasma multiplication in homologous cells and heterologous cells; (f) IR absorption: characteristic absorption at the following wave number (cm -1 ): 3600-2900 (strong), 1700-1500 (strong), 1440-1380 (medium), 1160-1080 (medium), and 550 (medium); (g) UV absorption: maximum absorption is found at 274-276 nm for 0.1 W/V % aqueous solution; (h) color reaction: positive Lowry-Folin process, Ninhydrin reaction, Phenol-sulfuric acid reaction and Elson-Morgan's reaction; (i) color and appearance: white and amorphous; the process comprising the steps of contacting at least one starting material selected from the group consisting of (A) blood plasma or serum obtained from a mammal hyperimmunized with a protozoan selected from the group consisting of Toxoplasma, Plasmodium and Babesia, (B) a culture supernatant of spleen cells from a manmal hyperimmunized with said protozoan, and (C) a culture supernatant of spleen cells from a normal mammal uncubated inthe presence of at least one of the supernatant (B) and a protozoan lysate antigen selected from the group consisting of Toxoplasma lysate antigen (TLA), Plasmodium lysate antigen (PLA) and Babesia lysate antigen (BLA); with about 0.01 to about 0.1 W/V % of a proteolytic enzyme for a time sufficient to liberate said glycoprotein from said starting material, heating the resulting lysate to inactivate the enzyme, separating and isolating said glycoprotein from the lysate.

Claim 12

A process for preparing a biologically active substance which is a glycoprotein having a molecular weight of 3,000 to 5,000 as determined by a gel filtration method and having activity to inhibit toxoplasma multiplication not only in homologous cells but also in heterologous cells, and further having the following physical and chemical properties: (a) solubility: freely soluble in water and practically insoluble in methanol, ethanol, ether benzene, chloroform and acetone; (b) constituent amino acid of protein portion: apartic acid, threonine, serine, glutamic acid, glycine, alanine, cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, lysine, tryptophan, histidine, arginine and proline; (c) aspartic acid, glutamic acid and lysine contents in total amino acids: 45 to 65% by weight; (d) PH: 7.0 to 7.2 (1 W/V % aqueous solution); (e) thermal stability: when 1 W/V % aqueous solution of the substance is heated at 60°±0.1° C. for 30 minutes, the solution still retains the immunoactivity to inhibit toxoplasma multiplication in homologous cells and heterologous cells; (f) IR absorption: characteristic absorption at the following wave number (cm -1 ): 3600-2900 (strong), 1700-1500 (strong), 1440-1380 (medium), 1160-1080 (medium), and 550 (medium); (g) UV absorption: maximum absorption is found at 274-276 nm for 0.1 W/V % aqueous solution; (h) color reaction: positive Lowry-Folin process, Ninhydrin reaction, Phenol-sulfuric acid reaction and Elson-Morgan's reaction; (i) color and appearance: white and amorphous; the process comprising the steps of contacting at least one starting material selected from the group consisting of (A) blood plasma or serum obtained from a mammal hyperimmunized with a protozoan selected from the group consisting of Toxoplasma, Plasmodium and Babesia, (B) a culture supernatant of spleen cells from a manmal hyperimmunized with said protozoan, and (C) a culture supernatant of spleen cells from a normal mammal uncubated inthe presence of at least one of the supernatant (B) and a protozoan lysate antigen selected from the group consisting of Toxoplasma lysate antigen (TLA), Plasmodium lysate antigen (PLA) and Babesia lysate antigen (BLA); with about 0.01 to about 0.1 W/V % of a proteolytic enzyme for a time sufficient to liberate said glycoprotein from said starting material, heating the resulting lysate to inactivate the enzyme, separating and isolating said glycoprotein from the lysate.